---
title: "Morphine Sulfat Market, Global Outlook and Forecast 2025-2032"
datePublished: Thu Oct 02 2025 21:42:31 GMT+0000 (Coordinated Universal Time)
cuid: cmg9xyb2o000202l50w1367tx
slug: morphine-sulfat-market-global-outlook-and-forecast-2025-2032

---

# Morphine Sulfat Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global morphine sulfate market size was valued at <strong>USD 2.34 billion in 2024 </strong>and is projected to reach <strong>USD 3.15 billion by 2032</strong>, exhibiting a <strong>CAGR of 3.8%</strong> during the forecast period (2025-2032). The opioid analgesic market remains steady despite regulatory challenges, primarily due to persistent demand for pain management in chronic disease treatment.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/293791/morphine-sulfat-forecast-market">
            https://www.24chemicalresearch.com/download-sample/293791/morphine-sulfat-forecast-market</a></b></div><br><p>
</p><p>Morphine sulfate is an opioid alkaloid derived from the opium poppy plant, clinically formulated as both immediate-release and extended-release preparations. As a <strong>Schedule II controlled substance</strong>, it serves as the gold standard for managing moderate-to-severe acute and chronic pain, particularly in cancer treatment and post-surgical care. The drug acts primarily on the central nervous system by binding to mu-opioid receptors, providing analgesia while carrying risks of tolerance and dependence.</p><p>
</p><p>The market shows resilience against alternative pain therapies because of morphine's <strong>irreplaceable efficacy in palliative care</strong>, with oncology applications accounting for approximately 40% of medical usage. North America dominates consumption patterns due to high prevalence of chronic pain conditions, while Asia-Pacific emerges as the fastest-growing region with improving healthcare infrastructure. Major pharmaceutical companies continue investing in abuse-deterrent formulations to address opioid misuse concerns while maintaining therapeutic accessibility.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Increasing Prevalence of Chronic Pain Conditions to Propel Market Growth</strong></p><p>
</p><p>Global morphine sulfate market is primarily driven by the rising prevalence of chronic pain conditions, including cancer pain, postoperative pain, and neuropathic pain. Recent data indicates that chronic pain affects approximately 20% of the global adult population, with cancer-related pain impacting over 55% of patients during treatment. Morphine sulfate, as a gold-standard opioid analgesic, remains an essential component in pain management protocols worldwide. Healthcare providers increasingly rely on morphine sulfate for moderate to severe pain relief due to its proven efficacy and well-established safety profile when used appropriately. The growing geriatric population, which is more susceptible to chronic pain conditions, further contributes to market expansion.</p><p>
</p><p style="text-align:center"><strong>Expansion of Palliative Care Services to Accelerate Market Demand</strong></p><p>
</p><p>The significant global expansion of palliative care services presents a major growth opportunity for the morphine sulfate market. Governments and healthcare organizations worldwide are increasingly recognizing the importance of palliative care, particularly for terminal illnesses. In developed nations, approximately 80% of palliative care programs incorporate morphine sulfate as a cornerstone therapy for pain management. Emerging economies are now implementing national palliative care policies, which include improved access to essential pain medications. The World Health Organization's essential medicines list continues to include morphine sulfate, reinforcing its critical role in healthcare systems. This institutional support ensures sustained market growth despite regulatory challenges in some regions.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in Drug Delivery Systems to Drive Innovation</strong></p><p>
</p><p>Pharmaceutical companies are investing heavily in developing advanced drug delivery systems for morphine sulfate to improve patient compliance and safety. Novel formulations including extended-release tablets, abuse-deterrent formulations, and targeted delivery systems are gaining traction in the market. These innovations address critical concerns about opioid misuse while maintaining therapeutic efficacy. For instance, recent advancements in polymer-based drug delivery systems have enabled more precise control of morphine release rates, reducing dosing frequency and minimizing peaks that could potentially lead to abuse. The development of these sophisticated formulations creates new revenue streams and extends patent protection for manufacturers.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Oversight and Opioid Crisis Aftermath to Limit Market Expansion</strong></p><p>
</p><p>The global opioid crisis has led to unprecedented regulatory scrutiny of morphine sulfate and related opioid medications. In major markets, new prescribing guidelines and risk evaluation programs have significantly impacted prescription volumes. Recent data shows that morphine sulfate prescriptions in the U.S. have declined by approximately 30% over the past five years due to these regulatory measures. Strict prescription monitoring programs, mandated physician education, and limitations on dispensing create substantial barriers to market growth. While these measures aim to curb opioid abuse, they also create challenges for legitimate patients requiring effective pain management.</p><p>
</p><p style="text-align:center"><strong>Emergence of Non-Opioid Alternatives to Constrain Market Potential</strong></p><p>
</p><p>The pharmaceutical industry is witnessing rapid development of non-opioid pain management alternatives, including novel NSAIDs, nerve blocks, and neuromodulation therapies. These alternatives are gaining preference, particularly for chronic non-cancer pain, due to their lower risk of dependence and fewer side effects. Clinical studies demonstrate that combination therapies using non-opioid medications can reduce morphine sulfate requirements by up to 40% in postoperative pain management. While morphine sulfate remains irreplaceable for certain conditions, the growing adoption of multimodal analgesia approaches represents a significant restraint on market growth. Healthcare providers are increasingly reserving opioid use for cases where non-opioid therapies prove ineffective.</p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities and Manufacturing Complexities to Impede Market Stability</strong></p><p>
</p><p>Morphine sulfate production faces unique challenges due to its controlled substance status and complex manufacturing requirements. The global supply chain remains vulnerable to disruptions, as seen during recent geopolitical conflicts and pandemic-related restrictions. API production is concentrated in a few regions, creating potential bottlenecks. Regulatory requirements for controlled substance manufacturing necessitate specialized facilities and security measures, increasing production costs by 15-20% compared to conventional pharmaceuticals. These factors contribute to periodic shortages and price volatility, particularly in developing markets where distribution networks are less robust.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Emerging Markets Expansion to Offer Significant Growth Prospects</strong></p><p>
</p><p>Developing nations in Asia, Africa, and Latin America present substantial growth opportunities for morphine sulfate manufacturers. While these regions currently account for less than 20% of global consumption, improving healthcare infrastructure and increasing cancer prevalence are driving demand. Many emerging markets are implementing policies to improve access to essential pain medications, with morphine sulfate often being the first opioid added to formularies. The establishment of local manufacturing facilities through partnerships or subsidiaries can help companies capitalize on this growing demand while addressing cost sensitivity through regional production.</p><p>
</p><p style="text-align:center"><strong>Development of Abuse-Deterrent Formulations to Create Competitive Advantage</strong></p><p>
</p><p>The development of next-generation abuse-deterrent formulations represents a major strategic opportunity in the morphine sulfate market. Current technologies including physical barriers, agonist-antagonist combinations, and novel delivery systems have shown promise in reducing misuse potential. Manufacturers investing in these innovations can differentiate their products in a competitive market while addressing regulatory concerns. Recent clinical data suggests that abuse-deterrent formulations can reduce inappropriate use by up to 60%, making them increasingly attractive to prescribers and payers. These value-added formulations command premium pricing and enjoy favorable reimbursement policies in many markets.</p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships and Vertical Integration to Enhance Market Position</strong></p><p>
</p><p>The morphine sulfate market presents significant opportunities for strategic collaborations across the pharmaceutical value chain. Partnerships between API manufacturers and finished dosage form producers can optimize costs and ensure supply chain resilience. Vertical integration strategies, particularly in emerging markets, enable companies to control quality and reduce regulatory risks. Recent industry trends show increasing M&amp;A activity in the controlled substances sector, with larger pharmaceutical companies acquiring specialized opioid manufacturers to strengthen their pain management portfolios. Such strategic moves allow companies to leverage existing regulatory approvals and distribution networks for accelerated market penetration.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Opioid Stigma and Prescriber Reluctance to Pose Significant Barriers</strong></p><p>
</p><p>The ongoing opioid crisis has created substantial prescriber hesitation regarding morphine sulfate, even for legitimate medical use. Recent surveys indicate that nearly 40% of primary care physicians express discomfort prescribing opioids, including morphine sulfate, due to fear of regulatory scrutiny or patient addiction. This reluctance is particularly pronounced for chronic non-cancer pain, where clinical guidelines increasingly recommend alternative therapies first. The challenge for manufacturers lies in balancing appropriate promotion of their products' medical benefits while acknowledging and addressing addiction risks. Comprehensive physician education programs and real-world evidence generation may help mitigate these concerns over time.</p><p>
</p><p style="text-align:center"><strong>Pricing Pressures and Reimbursement Limitations to Impact Profitability</strong></p><p>
</p><p>Morphine sulfate faces increasing pricing pressures across global markets, particularly for generic formulations. In the U.S., widespread genericization has led to price erosion of up to 70% for immediate-release formulations over the past decade. Payers are implementing stricter prior authorization requirements and step therapy protocols that delay or limit morphine sulfate use. Many healthcare systems have established prescription limits and mandatory risk-benefit assessments that complicate patient access. These economic challenges require manufacturers to develop sophisticated pricing strategies and demonstrate clear value differentiation for their products through clinical outcomes data and health economic analyses.</p><p>
</p><p style="text-align:center"><strong>Diversion Control and Security Requirements to Increase Operational Costs</strong></p><p>
</p><p>The controlled substance status of morphine sulfate imposes substantial security and compliance costs throughout the supply chain. Manufacturers must implement rigorous anti-diversion measures including tamper-resistant packaging, serialization, and sophisticated distribution tracking systems. Recent regulatory updates in major markets have strengthened these requirements, with compliance costs increasing by approximately 25% over the past three years. Wholesalers and pharmacies face similar challenges, with many small operators exiting the controlled substances market due to the burden of compliance. These factors contribute to higher product costs and potential access issues in certain regions, particularly rural areas with limited pharmacy networks.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Rising Demand for Pain Management Solutions to Drive Market Growth</strong></p><p>
</p><p>Global morphine sulfate market is experiencing steady growth, driven by the increasing prevalence of chronic pain conditions and the rising demand for effective pain management solutions. Morphine sulfate, a key opioid analgesic, remains a cornerstone in the treatment of severe pain, particularly in cancer and post-surgical care. The market is projected to grow at a CAGR of 3.8% from 2025 to 2032, reaching a valuation of $3.15 billion by 2032. The aging population, coupled with the rising incidence of chronic diseases, is further fueling the demand for morphine sulfate-based therapies.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Regulatory and Supply Chain Challenges</strong></p><p>
</p><p>Despite its medical benefits, the morphine sulfate market faces regulatory scrutiny due to concerns over opioid misuse and addiction. Governments worldwide are implementing stricter prescription guidelines and monitoring programs to curb abuse. Additionally, supply chain disruptions, particularly in regions like North America and Europe, have impacted the availability of raw materials, leading to price fluctuations. However, pharmaceutical companies are investing in advanced manufacturing techniques to ensure a stable supply of high-quality morphine sulfate formulations.</p><p>
<strong>Expansion of Palliative Care Services</strong></p><p>
</p><p>The expansion of palliative care services in emerging economies is creating new opportunities for the morphine sulfate market. Countries in Asia and Latin America are increasingly adopting palliative care programs to improve the quality of life for patients with terminal illnesses. This has led to higher demand for morphine sulfate in both oral and injectable forms. Furthermore, collaborations between governments and non-profit organizations are enhancing access to pain relief medications in underserved regions, supporting market growth.</p><p>
<strong>Technological Advancements in Drug Delivery</strong></p><p>
</p><p>Innovations in drug delivery systems are transforming the morphine sulfate market. Extended-release formulations and novel delivery methods, such as transdermal patches and implantable devices, are improving patient compliance and reducing the risk of misuse. Pharmaceutical companies are also focusing on developing abuse-deterrent formulations to address regulatory concerns. These advancements are expected to drive the adoption of morphine sulfate in both developed and developing markets.</p><p>
<strong>Competitive Landscape and Strategic Developments</strong></p><p>
</p><p>The morphine sulfate market is highly competitive, with key players like Mallinckrodt Pharmaceuticals, Alcaliber, and Purdue Pharma leading the industry. Companies are engaging in strategic partnerships, mergers, and acquisitions to strengthen their market position. Additionally, investments in research and development are driving the introduction of new morphine sulfate-based products. The entry of generic drug manufacturers is also intensifying competition, leading to price reductions and wider accessibility.Overall, the morphine sulfate market is poised for steady growth, supported by increasing demand for pain management solutions, technological advancements, and expanding healthcare infrastructure. However, regulatory challenges and the opioid crisis remain critical factors influencing market dynamics.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Market Dominance Fueled by Strategic Expansions and Regulatory Compliance</strong></p><p>
</p><p>Global morphine sulfate market exhibits a moderately consolidated structure, dominated by a mix of established pharmaceutical giants and regional specialists. <strong>Mallinckrodt Pharmaceuticals</strong> leads the market with an estimated 22% revenue share in 2024, driven by its comprehensive pain management portfolio and strong distribution network across 60+ countries. The company's recent FDA approvals for extended-release formulations have further solidified its position.</p><p>
</p><p>While North American and European players command the premium segment, <strong>SUN PHARMA</strong> and <strong>Qinghai Pharmaceutical</strong> are gaining traction through cost-effective generic alternatives. SUN PHARMA captured 14% of the Asian market last year through strategic acquisitions of local distributors, whereas Qinghai's government partnerships in emerging markets demonstrate how regional players are scaling operations.</p><p>
</p><p>Regulatory challenges around opioid prescriptions have prompted interesting adaptations. <strong>Purdue Pharma</strong>, despite restructuring, maintains technological superiority in abuse-deterrent formulations, holding 17 patents for tamper-resistant technologies. Meanwhile, <strong>Alcaliber</strong>'s vertical integration—from poppy cultivation to finished dosage forms—gives it unique supply chain advantages amidst raw material volatility.</p><p>
</p><p>The competitive intensity is escalating as mid-sized firms like <strong>Macfarlan Smith</strong> invest in API innovation. Their recently launched morphine sulfate with 99.7% purity grade has attracted partnership inquiries from three top-ten pharma companies, indicating how specialty manufacturers can carve niches in this regulated market.</p><p>
<strong>List of Key Morphine Sulfate Companies Profiled</strong></p><p>
</p><p>Mallinckrodt Pharmaceuticals (U.S.)</p><p>Alcaliber (Spain)</p><p>Purdue Pharma L.P. (U.S.)</p><p>Cepia-Sanofi (France)</p><p>Macfarlan Smith (UK)</p><p>SUN PHARMA (India)</p><p>Qinghai Pharmaceutical (China)</p><p>Taj Pharmaceuticals (India)</p><p>Northeast Pharm (China)</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Pills Segment Dominates Due to Widespread Use in Pain Management and Chronic Conditions</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Pills</p><p>Powder</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Oral Tablets Lead the Segment Owing to High Patient Compliance and Ease of Administration</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Oral Tablets</p><p>Injection</p><p>Capsule</p><p>Others</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Hospitals Remain the Primary Consumers Due to High Demand for Pain Management in Surgical Procedures</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Hospitals</p><p>Clinics</p><p>Retail Pharmacies</p><p>Online Pharmacies</p><p>
<strong>Regional Analysis: Morphine Sulfate Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
</p><p>The North American morphine sulfate market is driven by high demand for pain management solutions, particularly in the U.S., where an aging population and rising prevalence of chronic diseases fuel consumption. Strict regulatory oversight by the FDA and DEA ensures controlled distribution, while pharmaceutical companies focus on developing abuse-deterrent formulations to address opioid misuse concerns. The U.S. accounts for over 85% of regional market share, with major players like Mallinckrodt Pharmaceuticals and Purdue Pharma leading production. However, lawsuits and stricter prescribing guidelines have created market volatility. Canada’s market is smaller but growing steadily, supported by government healthcare programs.</p><p>
</p><p><strong>Europe</strong></p><p>
</p><p>Europe’s market demonstrates steady growth, with Germany, France, and the U.K. as primary consumers. The region benefits from universal healthcare systems that facilitate access to prescription opioids for legitimate medical use, though strict EMCDDA regulations limit over-prescription. Patented extended-release formulations dominate the premium segment, while generics gain traction in Eastern Europe. The EU’s focus on palliative care expansion and cancer pain management creates opportunities, but reimbursement policies vary significantly between countries. Regional manufacturers like Alcaliber (Spain) and Macfarlan Smith (U.K.) maintain strong supply chains while adapting to harmonized EU narcotics legislation.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
</p><p>Asia-Pacific represents the fastest-growing morphine sulfate market, with China and India emerging as both major producers and consumers. China’s relaxation of opioid prescription rules for cancer pain and India’s expanding pharmaceutical manufacturing sector drive growth. However, cultural stigma around opioid use and conservative prescribing practices in Japan and South Korea restrain market potential. Southeast Asian nations show increasing demand but face distribution challenges due to fragmented healthcare infrastructure. The region benefits from cost-competitive API production, with Indian firms like Sun Pharma exporting globally. Regulatory modernization efforts aim to balance medical access with drug control measures.</p><p>
</p><p><strong>South America</strong></p><p>
</p><p>South America presents a developing market, with Brazil accounting for nearly 60% of regional morphine sulfate consumption. Improving cancer care infrastructure and chronic pain recognition boost demand, though economic instability in Argentina and Venezuela limits market expansion. Regulatory frameworks vary widely – Brazil’s ANVISA maintains strict controls, while some Andean nations face illicit diversion risks. Local production remains limited, creating import dependency. Public healthcare systems dominate distribution, with private sector growth concentrated in urban centers. Increasing awareness of palliative care needs offers long-term growth potential despite current economic and political challenges.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
</p><p>This region shows the most uneven morphine sulfate distribution, with Gulf Cooperation Council (GCC) countries demonstrating advanced pain management protocols while sub-Saharan Africa experiences severe shortages. Saudi Arabia and UAE import high-quality formulations for their healthcare systems, but complex import regulations in North Africa create bottlenecks. Africa’s market remains largely underserved, with less than 1% of global morphine consumption despite bearing 25% of the global disease burden. Limited local manufacturing, cultural barriers, and inadequate training in pain management constrain growth. International aid programs work to improve access, particularly for HIV/AIDS and cancer patients, but significant infrastructure investment is needed.</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Morphine Sulfate, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Morphine Sulfate manufacturers, suppliers, and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Morphine Sulfate Market?</strong></p><p>
</p><p>-&gt; Global Morphine Sulfate market was valued at USD 2.34 billion in 2024 and is projected to reach USD 3.15 billion by 2032, at a CAGR of 3.8% during the forecast period from 2025 to 2032.</p><p>
<strong>Which key companies operate in Global Morphine Sulfate Market?</strong></p><p>
</p><p>-&gt; Key players include Mallinckrodt Pharmaceuticals, Alcaliber, Purdue Pharma, Cepia-Sanofi, Macfarlan Smith, SUN PHARMA, Qinghai Pharmaceutical, Taj Pharmaceuticals, and Northeast Pharm, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include rising prevalence of chronic pain conditions, increasing cancer cases, and advancements in pain management therapies.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; North America is the largest market, while Asia-Pacific is projected to grow at the highest CAGR during the forecast period.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include innovative drug delivery systems, increasing use in palliative care, and rising adoption in developing countries.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/293791/morphine-sulfat-forecast-market">
            https://www.24chemicalresearch.com/reports/293791/morphine-sulfat-forecast-market</a></b></div><br>
            <b>Table of Content:</b><p>Morphine Sulfat (CAS 64-31-3)<br />
This report aims to provide a comprehensive presentation of the global market for Morphine Sulfat, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Morphine Sulfat. This report contains market size and forecasts of Morphine Sulfat in global, including the following market information:<br />
Global Morphine Sulfat Market Revenue, 2020-2024, 2025-2035, ($ millions)<br />
Global Morphine Sulfat Market Sales, 2020-2024, 2025-2035, (K MT)<br />
Global top five Morphine Sulfat companies in 2024 (%)<br />
The global Morphine Sulfat market was valued at US$ million in 2024 and is projected to reach US$ million by 2032, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.<br />
The U.S. Market is Estimated at $ Million in 2024, While China is Forecast to Reach $ Million.<br />
Pills Segment to Reach $ Million by 2032, with a % CAGR in next six years.<br />
The global key manufacturers of Morphine Sulfat include Mallinckrodt Pharmaceuticals, Alcaliber, Purdue Pharma, Cepia-Sanofi, Macfarlan Smith, SUN PHARMA, Qinghai Pharmaceutical, Taj Pharmaceuticals and Northeast Pharm, etc. in 2024, the global top five players have a share approximately % in terms of revenue.<br />
We surveyed the Morphine Sulfat manufacturers, sup</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/293791/morphine-sulfat-forecast-market">
            https://www.24chemicalresearch.com/reports/293791/morphine-sulfat-forecast-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>